9INU image
Deposition Date 2024-07-08
Release Date 2025-03-12
Last Version Date 2025-03-12
Entry Detail
PDB ID:
9INU
Keywords:
Title:
Novel PD-L1/VISTA dual inhibitor as potential immunotherapy agents
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.28
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Programmed cell death 1 ligand 1
Gene (Uniprot):CD274
Chain IDs:A, B
Chain Length:128
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents.
J.Med.Chem. 68 156 173 (2025)
PMID: 39731560 DOI: 10.1021/acs.jmedchem.4c01640

Abstact

Inhibiting the activity of immune checkpoint proteins to reignite the antitumor activity of immune cells has emerged as a pivotal strategy. PD-L1 and VISTA, as critical proteins governing immune regulation, are concurrently upregulated under conditions such as hypoxia. Through a rational drug design process, P17, a dual-target inhibitor for PD-L1 and VISTA is identified. This inhibitor blocks the signaling pathways of both PD-L1 and VISTA at the protein and cellular levels, thereby reactivating the antitumor function of T cells. P17 displays encouraging attributes in terms of druggability and safety assessments. Notably, P17 demonstrates superior antitumor efficacy compared to single-target inhibitors at equivalent doses in in vivo experiments. More crucially, P17 significantly enhances the infiltration of immune cells. This study not only validates the effectiveness of a dual-target inhibitor strategy against PD-L1 and VISTA, but also identifies P17 as a promising candidate molecule with significant therapeutic potential.

Legend

Protein

Chemical

Disease

Primary Citation of related structures